NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts
NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts FORT WORTH (December 20, 2022) — NanOlogy LLC, a clinical-stage interventional oncology d ...
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer FORT WORTH (November 11, 2022) — NanOlogy LLC, a clinical-stage inte ...
NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX
NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX FORT WORTH, Texas--September 20, 2022--NanOlogy LLC, a clinical-stage interventional oncology drug c ...
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer FORT WORTH (August 1, 2022) — Na ...
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer FORT WORTH, Texas--NanOlogy LLC, a clini ...